Quantifying lead-time bias in risk factor studies of cancer through simulation.

[1]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[2]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[3]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[4]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[5]  K. Kafadar,et al.  Computational methods in medical decision making: to screen or not to screen? , 2005, Statistics in medicine.

[6]  T. Tammela,et al.  Test sensitivity of prostate‐specific antigen in the Finnish randomised prostate cancer screening trial , 2004, International journal of cancer.

[7]  M. Joffe.  Invited commentary: screening as a nuisance variable in cancer epidemiology: methodological considerations. , 2003, American journal of epidemiology.

[8]  N. Weiss.  Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it. , 2003, American journal of epidemiology.

[9]  M. Vercelli,et al.  Prostate cancer in Italy before and during the ‘PSA era’: survival trend and prognostic determinants , 2003, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[10]  S. Greenland,et al.  Estimating causal effects. , 2002, International journal of epidemiology.

[11]  S. Woolf,et al.  THE ACCURACY AND EFFECTIVENESS OF ROUTINE POPULATION SCREENING WITH MAMMOGRAPHY, PROSTATE-SPECIFIC ANTIGEN, AND PRENATAL ULTRASOUND , 2001, International Journal of Technology Assessment in Health Care.

[12]  J. Concato,et al.  A nested case-control study of the effectiveness of screening for prostate cancer: research design. , 2001, Journal of clinical epidemiology.

[13]  R. Anderson,et al.  Cancer screening guidelines. , 2001, American family physician.

[14]  F. Hamdy,et al.  Unanswered questions in screening for prostate cancer. , 2000, European journal of cancer.

[15]  M. Resnick,et al.  Analysis of recent trends in prostate cancer incidence and mortality , 2000, The Prostate.

[16]  T. Church.  A novel form of ascertainment bias in case-control studies of cancer screening. , 1999, Journal of clinical epidemiology.

[17]  E. Feuer,et al.  Asymptomatic incidence and duration of prostate cancer. , 1998, American journal of epidemiology.

[18]  P. Prorok,et al.  Case-control studies of cancer screening: theory and practice. , 1998, Journal of the National Cancer Institute.

[19]  G. Friedman,et al.  A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. , 1992, The New England journal of medicine.

[20]  S. Moss.  Case-control studies of screening. , 1991, International journal of epidemiology.

[21]  P. Prorok,et al.  Statistical considerations in cancer screening programs. , 1990, The Urologic clinics of North America.

[22]  M. Zelen.  Data analysis methods for inferring the natural history of chronic diseases. , 1971, National Cancer Institute monograph.

[23]  A. Kibel.  Mortality Results from a Randomized Prostate-Cancer Screening Trial , 2009 .

[24]  N. Weiss,et al.  Application of the case-control method in the evaluation of screening. , 1994, Epidemiologic reviews.

[25]  N. Day,et al.  Case-control studies for the evaluation of screening. , 1986, Journal of chronic diseases.